T urmeric (Curcuma longa)
Antioxidant, Anti-inflammatory and Anti-Cancer Herb
Turmeric (also known as curcumin), the bright yellow root used for centuries as a cooking
spice, is also a potent medicinal herb.
Turmeric is:
- anti-inflammatory
- antioxidant
- liver-protective (on a par with milk thistle)
- anti tumorgenic (helps prevent and may
even help reverse cancer)
- and helps maintain normal blood viscosity.
What more
could you ask for in a non-toxic, beautiful, fragrant herb?
Turmeric (Curcuma longa) This herb is a potent antioxidant
and anti-inflammatory. An ever-growing body of
evidence suggests that turmeric may both help prevent AND help reverse already-existing
cancers.
Each
High-Potency Capsule contains: 500 mg of turmeric, standardized
to 95% curcuminoids. (475mg
active curcuminoids).
Suggested dose 1
capsule, 2-3 times per day.
Product # 164 (60 Capsules)
$15.95
Enter Quantity Desired and Click "Add To Cart" Button
References
1.) Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, Yang H, Chu
W, Bi Z, Di W, Wan Y. Curcumin attenuates EGF-induced AQP3 up-regulation and
cell migration in human ovarian cancer cells.Cancer Chemother Pharmacol. 2008
Jan 23 [Epub ahead of print].
2.) Steward WP, Gescher AJ. Curcumin in cancer management: Recent results of
analogue design and clinical studies and desirable future research. Mol Nutr
Food Res. 2008 Jan 9 [Epub ahead of print].
3.) Shankar S, Ganapathy S, Chen Q, Srivastava RK. Curcumin sensitizes
TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and
angiogenesis. Mol Cancer. 2008 Jan 29;7(1):16 [Epub ahead of print]
4.) Moiseeva EP, Almeida GM, Jones GD, Manson MM. Extended treatment with
physiologic concentrations of dietary phytochemicals results in altered gene
expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther. 2007
Nov;6(11):3071-9.
5.) Shankar S, Chen Q, Sarva K, Siddiqui I, Srivastava RK. Curcumin enhances the
apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular
mechanisms of apoptosis, migration and angiogenesis. J Mol Signal. 2007 Oct
4;2:10.
6.) Shankar S, Srivastava RK. Bax and Bak genes are essential for maximum
apoptotic response by curcumin, a polyphenolic compound and cancer
chemopreventive agent derived from turmeric, Curcuma longa. Carcinogenesis. 2007
Jun;28(6):1277-86. Epub 2007 Feb 2.
7.) Shankar S, Srivastava RK. Involvement of Bcl-2 family members,
phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced
apoptosis in prostate cancer. Int J Oncol. 2007 Apr;30(4):905-18.
8.) Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP,
Rosengren RJ. The combination of epigallocatechin gallate and curcumin
suppresses ERalpha-breast cancer cell growth in vitro and in vivo. Int J Cancer.
2007 Dec 20 [Epub ahead of print].
9.) Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth
by suppressing gene expression of epidermal growth factor receptor through
reducing the activity of the transcription factor Egr-1. Oncogene. 2006 Jan
12;25(2):278-87.
10.) Wahl H, Tan L, Griffith K, Choi M, Liu JR. Curcumin enhances
Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol
Oncol. 2007 Apr;105(1):104-12. Epub 2006 Dec 15.
11.) Chen J, Wanming D, Zhang D, Liu Q, Kang J.Water-soluble antioxidants
improve the antioxidant and anticancer activity of low concentrations of
curcumin in human leukemia cells. Pharmazie. 2005 Jan;60(1):57-61.
12.) Deeb DD, Jiang H, Gao X, Divine G, Dulchavsky SA, Gautam SC.
Chemosensitization of hormone-refractory prostate cancer cells by curcumin to
TRAIL-induced apoptosis. J Exp Ther Oncol. 2005;5(2):81-91.
13.)Dobrovolskaia MA, Kozlov SV.: Inflammation and cancer: when NF-kappaB
amalgamates the perilous partnership. Curr Cancer Drug Targets. 2005
Aug;5(5):325-44.
14.) Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky
SA, Gautam SC. Curcumin sensitizes prostate cancer cells to tumor necrosis
factor-related apoptosis-inducing gand/Apo2L by inhibiting nuclear factor-kappaB
through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther. 2004
Jul;3(7):803-12.
15.) Van Erk MJ, Teuling E, Staal YC, Huybers S, Van Bladeren PJ, Aarts JM, Van
Ommen B. Time- and dose-dependent effects of curcumin on gene expression in
human colon cancer cells. J Carcinog. 2004 May 12;3(1):8.
16.)Ernst P.: The role of inflammation in the pathogenesis of gastric cancer.
Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:13-8
17.) Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and
catechin. Cancer Lett 1999;141:159–65.
18.) Khafif A, Schantz SP, Chou TC, Edelstein D, Sacks PG. uantitation of
chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in
normal, premalignant
and malignant human oral epithelial cells. Carcinogenesis. 1998
19. Sreejayan N, Rao MNA. Free radical scavenging activity of curcuminoids.
Arzneimittelforschung 1996;46:169–71.
20. Ramirez-Boscá A, Soler A, Gutierrez MAC, et al. Antioxidant curcuma extracts
decrease the blood lipid peroxide levels of human subjects. Age 1995;18:167–9.
21. Arora RB, Basu N, Kapoor V, Jain AP. Anti-inflammatory studies on Curcuma
longa (turmeric). Ind J Med Res 1971;59:1289–95.
22. Kiso Y, Suzuki Y, Watanbe N, et al. Antihepatotoxic principles of Curcuma
longa rhizomes. Planta Med 1983;49:185–7.
23. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic effect of
curcumin. Thromb Res 1985;40:413–7.
24. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and
catechin. Cancer Lett 1999;141:159–65. |
